StockNews.com Downgrades Immunic (NASDAQ:IMUX) to Sell

Immunic (NASDAQ:IMUX) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday.

Several other research firms have also recently issued reports on IMUX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a research report on Friday, February 21st. D. Boral Capital restated a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Stock Performance

NASDAQ:IMUX opened at $1.15 on Thursday. The stock has a fifty day moving average price of $1.06 and a two-hundred day moving average price of $1.22. The stock has a market capitalization of $103.59 million, a price-to-earnings ratio of -0.93 and a beta of 1.89. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11.

Institutional Trading of Immunic

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp increased its position in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares in the last quarter. 683 Capital Management LLC increased its position in Immunic by 2.2% during the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after purchasing an additional 15,349 shares in the last quarter. Bridgeway Capital Management LLC increased its position in Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares in the last quarter. Focus Partners Wealth increased its position in Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after purchasing an additional 23,610 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Immunic during the 3rd quarter worth about $50,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.